Antifibrotic dose changes not clearly tied to IPF progression risk

This retrospective study used two US data sources, the Pulmonary Fibrosis Foundation Patient Registry and Duke University Health System electronic health records, to examine whether reducing or stopping nintedanib or pirfenidone affected disease progression in patients with idiopathic pulmonary fibrosis. The study reported that dose reductions and discontinuations were common, and that time to progression (a composite of lung function decline, hospitalization, transplant, or death) did not differ significantly between patients who reduced or stopped antifibrotics and those who remained on full dose in either cohort. The authors noted that disease progression occurred in a substantial proportion of patients regardless of dosing strategy, highlighting an ongoing need for more effective and better-tolerated IPF therapies.

Most relevant for: Patients with idiopathic pulmonary fibrosis who are on or considering antifibrotic therapy with nintedanib or pirfenidone.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.